This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Henry Ford Health's Center for Structural Heart Disease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heartfailure patient on February 13, 2024 at Henry Ford Hospital in Detroit. However, only about 8,000 tricuspid valve surgeries are performed annually.
Highlights include: Due to the aging population and improvement in diagnostic strategies, the prevalence of heartvalve disease is expected to double by 2040 and triple by 2060.As As a result, it is estimated that the number of patients requiring heartvalve interventions will increase significantly in the coming decades.
Tricuspid and mitral valves are debilitating conditions that can lead to arrhythmias, hypertension, and heartfailure. Until recently, therapeutic options for people with tricuspid and mitral valve disorders have been limited to symptom relief or high-risk surgery.
13, 2025 Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is helping to provide more treatment options to people living with tricuspid valve disease. How has treatment for tricuspid valve disease evolved? Image by Getty. tim.hodson Tue, 02/18/2025 - 10:08 Feb.
When the valve narrows, it does not open or close properly, making the heart work harder to pump blood throughout the body. Eventually, this causes the heart to weaken and function poorly, which may lead to heartfailure and increased risk for sudden cardiac death. Presented at HeartValve Society 2024, Boston, MA.
When the valve narrows, it does not open or close properly, making the heart work harder to pump blood throughout the body. Eventually, this causes the heart to weaken and function poorly, which may lead to heartfailure and increased risk for sudden cardiac death. Presented at HeartValve Society 2024, Boston, MA.
suffer from heartfailure , and there are approximately 400,000 heart-failure-related deaths in this country each year. Patients with heartfailure often experience reduced mobility, quality of life and ability to work; the disease also represents a significant public health care burden.
Tricuspid and mitral valves are debilitating conditions that can lead to arrhythmias, hypertension, and heartfailure. Until recently, therapeutic options for people with tricuspid and mitral valve disorders have been limited to symptom relief or high-risk surgery.
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)
13, 2025 Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is helping to provide more treatment options to people living with tricuspid valve disease. How has treatment for tricuspid valve disease evolved? Image by Getty. tim.hodson Tue, 02/18/2025 - 10:08 Feb.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content